Dr Gesine Meyer-Rath [Assistant Professor ]

T: +27 (0) 10 001 0636  
Dr Gesine Meyer-Rath

Gesine Meyer-Rath, MD, PhD, is a physician, health economist, and infectious disease modeller with fourteen years experience in economic evaluations of health care interventions. She is a Research Assistant Professor of International Health at the Boston University Center for Global Health & Development.She has been resident in South Africa since 2006, and joined HE2RO in 2009. Dr. Meyer-Rath’s research focus lies on modelling methods for economic evaluation, including infectious disease modelling and decision analysis, and translating research into recommendations for public policy. Most of her work has centered on providing recommendations and budgets based on economic analysis for the South African HIV Programme, including a well-used budget impact model for ART, the National ART Cost Model, work on optimising HIV testing modalities, and leading the modelling work on the South African HIV Investment Case. Before joining HE2RO, she worked in the Paediatrics Department of Charité University Hospital Berlin, with the CHOICE team of the World Health Organization, and as a researcher at the London School of Hygiene and Tropical Medicine and the Reproductive Health and HIV Research Unit of the University of the Witwatersrand (now Wits Reproductive Health and HIV Research Institute). She is the author of over 40 peer-reviewed articles and several book chapters on HIV economics. She holds an MD/PhD from Humboldt University and Free University, Berlin, Germany, and a PhD in Health Economics at the London School of Hygiene and Tropical Medicine.

Projects

  • Supporting the South African HIV/TB Investment Case

    Since 2011, UNAIDS and other international organisations have prompted countries to counter the downward trend in international funding for HIV programmes by developing an investment case for their national HIV responses. These cases aim to maximise the impact of programmes on HIV incidence and deaths by correcting any mismatch between the epidemic and the response, identifying how to go to the required scale and maintain it, cutting unnecessary costs and diversions of capacity while generating 
  • Analysing the Impact and Cost of Scaling up Xpert MTB/RIF Technology for TB Diagnosis: The National TB Cost Model (NTCM)

    In the South African context, smear microscopy and other conventional TB diagnostic technologies that have been used for decades, are no longer reliable, because many HIV-positive tuberculosis patients are smear-negative, and the long time to diagnosis means that many patients die without having started TB treatment. In December 2010 the GeneXpert System using the Xpert MTB/RIF assay received a strong recommendation from the World Health Organization as the initial test in individuals with HIV 
  • Building HIV Financial Planning and Budgeting Capacity at Provincial Level: The FIN-CAP Project

    While treatment guidelines and the overall funding envelope for antiretroviral treatment in South Africa are decided at the level of the national department of health, the implementation of programmes is the responsibility of each of the nine provinces. In the past, implementation was jeopardized by the lack of capacity for financial planning, expenditure tracking and performance monitoring at the level of provincial HIV and finance managers. The FIN-CAP project, implemented by staff from 
  • Modelling the Cost of the National ART Programme under Different Sets of Guidelines: The National ART Cost Model (NACM) and the Treatment as Prevention Cost Model (TasP Cost Model)

    On request of the South African Department of Health (NDoH), since 2009 HE2RO has used the detailled cost and outcomes data collected in other projects to develop mathematical models projecting the size of the treatment cohort under different scenarios of antiretroviral treatment (ART eligibility as well as the resulting costs). Our budget models, most notably the National ART Cost Model (NACM) and the Treatment as Prevention Cost Model (TasP Cost Model), have contributed to several sets of 
  • Second and Third-Line Antiretroviral Regimens

    As South Africa continues its rapid expansion of access to first-line antiretroviral therapy (ART), more patients will need to be switched to second-line therapy as these first-line regimens fail. However, with little experience with second-line treatments in resource-limited settings, it is not clear how well patients will do on these medications if their first regimen fails. As the cost of second-line medications is much higher than first-line, it is critical to evaluate whether these 

Publications